VEGFA and hepatocellular carcinoma: Bevacizumab is an anti-VEGF antibody that targets tumour angiogenesis and has proven benefit in many solid tumours (Hurwitz et al, 2004; Miller et al, 2005; Sandler et al, 2006); bevacizumab has also been investigated in advanced HCC in a phase II setting.